Raymond P. Warrell, Jr., M.D.
Chairman and Chief Executive Officer
Raymond P. Warrell, Jr., M.D. has been our Chief Executive Officer and a member of our Board since December 1999 and our Chairman since January 2001. From 1978 to 1999, Dr. Warrell was associated with the Memorial Sloan-Kettering Cancer Center in New York, where he held tenured positions as Member, Attending Physician, and Associate Physician-in-Chief, and with the Cornell University Medical College, where he was Professor of Medicine.
Dr. Warrell also has more than 20 years of development and consulting experience in pharmaceuticals and biotechnology products. He was a co-founder and chairman of the scientific advisory board of PolaRx Biopharmaceuticals, Inc., which originated Trisenox®, a drug for the treatment of acute promyelocytic leukemia.
Dr. Warrell holds or has filed numerous patents and patent applications for biomedical therapeutic or diagnostic agents. He has published more than 100 peer-reviewed papers and more than 240 book chapters and abstracts, most of which are focused upon drug development in oncology.
Dr. Warrell is a member of the American Society of Clinical Investigation, the American Society of Hematology, the American Association for Cancer Research and the American Society of Clinical Oncology. Among many awards, he has received the U.S. Public Health Service Award for Exceptional Achievement in Orphan Drug Development from the FDA.
Loretta M. Itri, M.D., F.A.C.P.
President, Pharmaceutical Development and Chief Medical Officer
Dr. Itri is President, Pharmaceutical Development and Chief Medical Officer. Previously, Dr. Itri was Senior Vice President, Worldwide Clinical Affairs, and Chief Medical Officer at Ortho Biotech Inc., a Johnson & Johnson company.
As the senior clinical leader at Ortho Biotech and previously at J&J’s R.W. Johnson Pharmaceutical Research Institute (PRI), she led the clinical teams responsible for NDA approvals for Procrit® (epoetin alpha), that company’s largest single product. She had similar leadership responsibilities for the approvals of Leustatin®, Renova®, Topamax®, Levaquin®, and Ultram®.
Prior to joining J&J, Dr. Itri was associated with Hoffmann-La Roche, most recently as Assistant Vice President and Senior Director of Clinical Investigations, where she was responsible for all phases of clinical development programs in immunology, infectious diseases, antivirals, AIDS, hematology, and oncology.
Under her leadership in the areas of recombinant proteins, cytotoxic drugs and differentiation agents, the first successful Product License Application (PLA) for any interferon product Roferon-A® (interferon alfa) was compiled.
Dr. Itri has published more than 60 peer-reviewed original articles and book chapters in the field of oncology and has served as a member of the NIH Board of Scientific Counselors in the Division of Cancer Treatment as well as the Division of Cancer Prevention and Control.
W. Lloyd Sanders
Senior Vice President & Chief Operating Officer
Mr. Sanders assumed responsibility as COO in April 2008 after heading Genta's sales & marketing and worldwide commercial operations for 2 years.
Prior to joining Genta, Mr. Sanders held key senior leadership positions in the commercial organizations of Pharmacia (now Pfizer), Sanofi-Synthelabo and subsequently Sanofi-Aventis. He served at the Vice-President level within the Oncology commercial organizations of Sanofi-Aventis and Sanofi-Synthelabo.
In those roles, he had key responsibilities for the commercial success of Eloxatin® (oxaliplatin), Taxotere® (docetaxel), Anzemet® (dolasetron mesylate), and ELITEK® (rasburicase). He led the successful restructuring, integration, deployment, strategic development, and tactical execution of the merged companies' sales forces.
He was responsible for national account GPO contracting strategy and negotiations, and he shared responsibility for oncology sales training and sales operations. At Sanofi-Synthelabo, he led the 110-member team that achieved record sales for an oncology product launch with Eloxatin® (oxaliplatin).
From 1987 to 2002, Mr. Sanders held progressively increasing levels of responsibility at Pharmacia, Inc. (now Pfizer) participating in the launches of Camptosar® (irinotecan) and ELLENCE® (epirubicin). Mr. Sanders holds a Bachelor of Business Administration from Memphis State University.
Gary Siegel
Vice President, Finance
Gary Siegel joined Genta in May 2003 as Director, Financial Services, was appointed Senior Director, Financial Services in April 2004 and was appointed Vice President, Finance in September 2007. During his tenure at Genta, Mr. Siegel has been responsible for the day-to-day accounting and financial operations of the Company including public and management reporting, treasury operations, planning, financial controls and compliance.
Prior to joining Genta, he worked for two years at Geller & Company, a private consulting firm, where he led the management reporting for a multi-billion dollar client. His twenty-two years of experience in the pharmaceutical industry include leadership roles at Warner-Lambert Company and Pfizer Inc., where he held positions of progressively increasing levels of responsibility including Director, Corporate Finance and Director, Financial Planning & Reporting.
